suramin has been researched along with Mucopolysaccharidoses in 8 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Mucopolysaccharidoses: Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The trypanocidal drug suramin was previously reported to induce mucopolysaccharidosis in rats; apart from the biochemical demonstration of increased tissue concentrations of sulfated glycosaminoglycans (GAGs), a strongly positive staining reaction with the cationic dye Alcian Blue was taken as indicating GAG-storage (Constantopoulos et al." | 7.67 | On the alcianophilia of the drug suramin used as a tool for inducing experimental mucopolysaccharidosis. ( Christensen, B; Lüllmann-Rauch, R, 1988) |
| "Rats treated with the trypanocidal drug suramin, a potent inhibitor of several lysosomal enzymes, develop a storage disorder which mimics the features of mucopolysaccharidosis (Constantopoulos et al." | 7.67 | The suramin-treated rat as a model of mucopolysaccharidosis: reversibility of biochemical and morphological changes in the liver. ( Brady, R; Constantopoulos, G; Rees, S, 1986) |
| "We have examined the reversibility of the biochemical and pathological changes induced in the spleen, kidney and lung of the suramin-treated rat which we have previously proposed as a useful model of the human condition, mucopolysaccharidosis (MPS)." | 7.67 | The suramin-treated rat as a model of mucopolysaccharidosis. Variation in the reversibility of biochemical and morphological changes among different organs. ( Brady, RO; Constantopoulos, G; Rees, S, 1986) |
| "The trypanocidal drug suramin causes glycosaminoglycan and sphingolipid accumulation in the rat, thus simulating a mucopolysaccharidosis (Constantopoulos et al." | 7.66 | Organomegaly and histopathology in an animal model of mucopolysaccharidosis induced by suramin. ( Barranger, JA; Brady, RO; Constantopoulos, G; Rees, S, 1982) |
| "The suramin-treated rat may be a useful experimental animal model of mucopolysaccharidosis." | 5.26 | Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. ( Barranger, JA; Brady, RO; Constantopoulos, G; Cragg, BG; Rees, S, 1980) |
| "In vivo studies were carried out on dental tissues of rat incisor after a single injection of suramin, a drug which induces mucopolysaccharidosis-like disease." | 3.68 | [Lysosomal storage diseases, genetic or drug-induced? effect of glycosaminoglycan and sphingolipid disorders on dental tissues]. ( Bloch-Zupan, A; Goldberg, M; Gritli, A; Lécolle, S; Legrand, JM; Ruch, JV; Septier, D, 1993) |
| "The trypanocidal drug suramin was previously reported to induce mucopolysaccharidosis in rats; apart from the biochemical demonstration of increased tissue concentrations of sulfated glycosaminoglycans (GAGs), a strongly positive staining reaction with the cationic dye Alcian Blue was taken as indicating GAG-storage (Constantopoulos et al." | 3.67 | On the alcianophilia of the drug suramin used as a tool for inducing experimental mucopolysaccharidosis. ( Christensen, B; Lüllmann-Rauch, R, 1988) |
| "Rats treated with the trypanocidal drug suramin, a potent inhibitor of several lysosomal enzymes, develop a storage disorder which mimics the features of mucopolysaccharidosis (Constantopoulos et al." | 3.67 | The suramin-treated rat as a model of mucopolysaccharidosis: reversibility of biochemical and morphological changes in the liver. ( Brady, R; Constantopoulos, G; Rees, S, 1986) |
| "We have examined the reversibility of the biochemical and pathological changes induced in the spleen, kidney and lung of the suramin-treated rat which we have previously proposed as a useful model of the human condition, mucopolysaccharidosis (MPS)." | 3.67 | The suramin-treated rat as a model of mucopolysaccharidosis. Variation in the reversibility of biochemical and morphological changes among different organs. ( Brady, RO; Constantopoulos, G; Rees, S, 1986) |
| "The trypanocidal drug suramin causes glycosaminoglycan and sphingolipid accumulation in the rat, thus simulating a mucopolysaccharidosis (Constantopoulos et al." | 3.66 | Organomegaly and histopathology in an animal model of mucopolysaccharidosis induced by suramin. ( Barranger, JA; Brady, RO; Constantopoulos, G; Rees, S, 1982) |
| "The suramin-treated rat may be a useful experimental animal model of mucopolysaccharidosis." | 1.26 | Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. ( Barranger, JA; Brady, RO; Constantopoulos, G; Cragg, BG; Rees, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (75.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Constantopoulos, G | 5 |
| Rees, S | 5 |
| Cragg, BG | 2 |
| Barranger, JA | 3 |
| Brady, RO | 4 |
| Goldberg, M | 2 |
| Gritli, A | 2 |
| Bloch-Zupan, A | 1 |
| Septier, D | 2 |
| Lécolle, S | 1 |
| Legrand, JM | 1 |
| Ruch, JV | 1 |
| Christensen, B | 1 |
| Lüllmann-Rauch, R | 1 |
| Brady, R | 1 |
8 other studies available for suramin and Mucopolysaccharidoses
| Article | Year |
|---|---|
Suramin-induced storage disease. Mucopolysaccharidosis.
Topics: Animals; Cerebral Cortex; Disease Models, Animal; Humans; Kidney; Liver; Lung; Mucopolysaccharidoses | 1983 |
Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat.
Topics: Age Factors; Animals; Brain Chemistry; Disease Models, Animal; Dose-Response Relationship, Drug; Gly | 1980 |
Organomegaly and histopathology in an animal model of mucopolysaccharidosis induced by suramin.
Topics: Animals; Brain; Female; Kidney; Liver; Lung; Male; Mucopolysaccharidoses; Myocardium; Nucleic Acids; | 1982 |
[Lysosomal storage diseases, genetic or drug-induced? effect of glycosaminoglycan and sphingolipid disorders on dental tissues].
Topics: Ameloblasts; Animals; Child; Dentin; Glycosaminoglycans; Humans; In Vitro Techniques; Leukodystrophy | 1993 |
Suramin-induced mucopolysaccharidosis in rat incisor.
Topics: Ameloblasts; Animals; Disease Models, Animal; Glycosaminoglycans; Incisor; Lipidoses; Male; Microsco | 1993 |
On the alcianophilia of the drug suramin used as a tool for inducing experimental mucopolysaccharidosis.
Topics: Alcian Blue; Animals; Female; Glycosaminoglycans; Indoles; Molecular Conformation; Mucopolysaccharid | 1988 |
The suramin-treated rat as a model of mucopolysaccharidosis: reversibility of biochemical and morphological changes in the liver.
Topics: Animals; Body Weight; Glycosaminoglycans; Hydrolases; Liver; Lysosomes; Male; Microscopy, Electron; | 1986 |
The suramin-treated rat as a model of mucopolysaccharidosis. Variation in the reversibility of biochemical and morphological changes among different organs.
Topics: Animals; Disease Models, Animal; Glycosaminoglycans; Kidney; Lung; Lysosomes; Male; Microscopy, Elec | 1986 |